View in EDS HTML Full Text PDF Full Text

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).

Saved in:
Bibliographic Details
Title: Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Authors: Kobayashi K; Department of Breast Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan. kokorok-medicaloncology@memoad.jp., Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan., Mizuno T; Department of Medical Oncology, Mie University Hospital, Tsu, Japan., Miura K; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Tokuda Y; Breast Center, Seirei Yokohama Hospital, Yokohama, Japan., Yoshinami T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita, Japan., Kawaguchi H; Department of Breast Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan., Ohtani S; Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan., Saeki T; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan., Toi M; Department of Breast Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan., Takeuchi M; Graduate School of Mathematical Sciences, The University of Tokyo, Tokyo, Japan., Ito Y; Department of Breast Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Oct; Vol. 201 (3), pp. 409-415. Date of Electronic Publication: 2023 Jul 22.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37480384
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kobayashi+K%22">Kobayashi K</searchLink>; Department of Breast Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan. kokorok-medicaloncology@memoad.jp.<br /><searchLink fieldCode="AU" term="%22Masuda+N%22">Masuda N</searchLink>; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Mizuno+T%22">Mizuno T</searchLink>; Department of Medical Oncology, Mie University Hospital, Tsu, Japan.<br /><searchLink fieldCode="AU" term="%22Miura+K%22">Miura K</searchLink>; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Tokuda+Y%22">Tokuda Y</searchLink>; Breast Center, Seirei Yokohama Hospital, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Yoshinami+T%22">Yoshinami T</searchLink>; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.<br /><searchLink fieldCode="AU" term="%22Kawaguchi+H%22">Kawaguchi H</searchLink>; Department of Breast Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan.<br /><searchLink fieldCode="AU" term="%22Ohtani+S%22">Ohtani S</searchLink>; Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.<br /><searchLink fieldCode="AU" term="%22Saeki+T%22">Saeki T</searchLink>; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.<br /><searchLink fieldCode="AU" term="%22Toi+M%22">Toi M</searchLink>; Department of Breast Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan.<br /><searchLink fieldCode="AU" term="%22Takeuchi+M%22">Takeuchi M</searchLink>; Graduate School of Mathematical Sciences, The University of Tokyo, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Ito+Y%22">Ito Y</searchLink>; Department of Breast Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2023 Oct; Vol. 201 (3), pp. 409-415. <i>Date of Electronic Publication: </i>2023 Jul 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37480384
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-023-07030-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 409
    Titles:
      – TitleFull: Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kobayashi K
      – PersonEntity:
          Name:
            NameFull: Masuda N
      – PersonEntity:
          Name:
            NameFull: Mizuno T
      – PersonEntity:
          Name:
            NameFull: Miura K
      – PersonEntity:
          Name:
            NameFull: Tokuda Y
      – PersonEntity:
          Name:
            NameFull: Yoshinami T
      – PersonEntity:
          Name:
            NameFull: Kawaguchi H
      – PersonEntity:
          Name:
            NameFull: Ohtani S
      – PersonEntity:
          Name:
            NameFull: Saeki T
      – PersonEntity:
          Name:
            NameFull: Toi M
      – PersonEntity:
          Name:
            NameFull: Takeuchi M
      – PersonEntity:
          Name:
            NameFull: Ito Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2023 Oct
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 201
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1